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 Introduction 
 The complex regional pain syndrome (CRPS) is char-
acterized by neuropathic pain, sensory disturbances, tro-
phic, autonomic and motor changes of the affected ex-
tremity  [1, 2] . The pathogenesis of this syndrome may 
include abnormal neuronal processing and central sensi-
tization  [3–5] as well as complex communications be-
tween the nervous and the immune system resulting in 
chronic inflammation, pain and trophic changes  [6] 
which are mediated in part by catecholamines and stress 
 [7, 8] . The endocannabinoid system (ECS) has recently 
been shown to represent a critical mediator between 
stress, neuropathic pain and immunologic changes in-
cluding neuroinflammation  [9] and may therefore play a 
role in the development and symptom persistence in 
CRPS. The ECS includes the endocannabinoids anan-
damide and 2-arachidonoylglycerol (2-AG)  [10] which 
are functionally related to   9 -tetrahydrocannabinol. Two 
different types of G protein-coupled receptors, namely 
CB 1 receptors which are found mainly in the central ner-
vous system  [11] and CB 2 receptors with a peripheral dis-
tribution, especially on immunocompetent cells  [12, 13] , 
and the transient receptor potential vanilloid 1 (TRPV1) 
channels  [14] mediate the effects of the endocannabi-
noids. Based on experiments in rodents, both CB 1 and 
CB 2 receptors participate in central and peripheral can-
nabinoid-induced analgesia  [15, 16] and anti-inflamma-
 Key Words 
 Complex regional pain syndrome   Stress   Pain   
Endocannabinoid   Anandamide 
 Abstract 
 The complex regional pain syndrome (CRPS) is a disabling 
neuropathic pain condition that may develop following in-
juries of the extremities. The pathogenesis of this syndrome 
is not clear; however, it includes complex interactions be-
tween the nervous and the immune system resulting in 
chronic inflammation, pain and trophic changes. This inter-
action may be mediated by chronic stress which is thought 
to activate the endogenous cannabinoid (endocannabi-
noid) system (ECS). We conducted an open, prospective, 
comparative clinical study to determine plasma level of the 
endocannabinoid anandamide by high-performance liquid 
chromatography and a tandem mass spectrometry system 
in 10 patients with CRPS type I versus 10 age- and sex-
matched healthy controls. As compared to healthy controls, 
CRPS patients showed significantly higher plasma concen-
trations of anandamide. These results indicate that the pe-
ripheral ECS is activated in CRPS. Further studies are war-
ranted to evaluate the role of the ECS in the limitation of 
inflammation and pain.  Copyright © 2009 S. Karger AG, Basel 
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tion  [17, 18] , and appear to be activated under conditions 
of stress  [9, 19] . The TRPV1 channel is involved in the 
control of neurotransmitter release  [14] .
 Very little is known about the role of the ECS in hu-
mans with neuropathic pain in general and with CRPS in 
particular. We therefore measured the endocannabinoid 
anandamide in plasma of patients with CRPS. Our pri-
mary hypothesis to be tested was that the peripheral ECS 
is activated, and thus anandamide levels are elevated in 
patients with CRPS compared to healthy participants.
 Materials and Methods 
 Patients 
 Ten female CRPS type I patients (46.0  8 10.7 years, range 
20–55) admitted to the Interdisciplinary Pain Clinic of the De-
partment of Anesthesiology of the University of Munich, Ger-
many, were enrolled for blood withdrawal ( table 1 ) if they pro-
vided informed consent (local ethics committee protocol No. 
324/02) and met the criteria for CRPS type I as proposed by the 
International Association for the Study of Pain  [20] and Bruehl et 
al.  [21] . Ten age- and sex-matched healthy individuals (7 female, 
3 male; 41.9  8 7.3 years, range 34–50) who were completely free 
of medication served as controls. Exclusion criteria were preg-
nancy, infection or other inflammation disorders, cancer, muscle 
or joint diseases, motor trauma and treatment with glucocorti-
coids or other immunosuppressive drugs. All subjects had ab-
stained from their medication for at least 24 h before blood sam-
pling. In CRPS patients, we determined the duration and localiza-
tion of the disorder, and the pain intensities on a visual analogue 
scale (pain scores, 10-cm scale). The Mainz Pain Staging System 
was used to classify pain chronicity  [22] . The incidence and inten-
sity of chronic stress symptoms were evaluated by the Posttrau-
matic Stress Symptom-10 questionnaire  [23] .
 Biochemical Measurements and Anandamide Determination 
 All biochemical measurements were conducted in a blinded 
fashion with regard to group assignment of patients and controls. 
Venous blood sampling (500   l) was performed from the unaf-
fected limb. Because of effects of circadian rhythm on endocrine 
measurements, the time point of blood sampling during the day 
was standardized (between 10 and 11 a.m.) as was the time inter-
val from blood sampling until processing which ranged from 7 to 
10 min and did not differ between the groups (p  1 0.50). This time 
interval is particularly important with regard to endocannabi-
noid measurements  [24] .
 For determination of anandamide concentrations, we applied 
automated on-line solid phase extraction using column switching 
with subsequent direct transfer to high-performance liquid chro-
matography and a tandem mass spectrometry system (Waters 
Quattro Ultima Pt; Waters Corporation, Milford, Mass., USA) 
with stable isotope-labeled anandamide (4-fold deuterated) as the 
internal standard. Electrospray ionization in the positive mode 
was used; the following mass transitions were monitored: native 
anandamide, 348  1 62 and 4d3-anandamide (internal standard), 
352  1 66. Our method has a linear response from 100 to 1   g/l 
anandamide and a total coefficient of variation of 10.6% at a mean 
concentration of 8.5   g/l  [24] .
 Furthermore, a standard set of laboratory values (hemoglobin, 
leukocyte counts, C-reactive protein) was measured in both pa-
tients and healthy controls.
 Statistics 
 Normal distribution of sample data was confirmed by the Kol-
mogorov-Smirnov test. Geometric means were compared by Stu-
dent’s t test and considered to be significantly different at p  ! 0.05. 
Results are expressed as means  8 standard deviation.
 Results 
 Patient Characterization 
 There was no significant difference with regard to age 
(46.0  8 10.7 years, range 20–55 vs. 41.9  8 7.3 years, 
range 34–50; p = 0.33) and sex distribution (p = 0.21) be-
tween CRPS patients and controls.
 CRPS patients had a mean disease duration of 22 
months. The mean pain score in CRPS patients was 3.9 
 8 0.5 on the 10-cm visual analogue scale. According to 
the criteria of the Mainz Pain Staging System classifica-
tion, 3 patients belonged to stage I, 4 patients had pain 
chronicity of stage II and 3 patients fulfilled criteria for 
advanced pain chronification (stage III). The Posttrau-
matic Stress Symptom-10 score in the CRPS study popu-
lation was higher (35.2  8 5.3) than in healthy controls 
(20.8  8 4.8; p  ! 0.01).
 Standard Laboratory Values 
 The standard set of laboratory values in patients with 
CRPS was in the normal range and not statistically dif-
ferent from healthy controls (data not shown).
 Anandamide Concentrations 
 CRPS patients had significantly higher plasma con-
centrations (3.97  8 1.49 ng/ml) of anandamide than 
healthy controls (1.44  8 0.36 ng/ml; p  ! 0.001; 95% con-
fidence interval –3.55 to –1.51;  fig. 1 ). The power of the 
performed test with   = 0.05 is 0.999.
 Discussion 
 The major finding of this study is an increased plasma 
concentration of the endocannabinoid anandamide in 
patients with a long-standing and chronic neuropathic 
pain syndrome, namely CRPS. Chronic stress as a result 
of ongoing neuropathic pain or stressful life events is a 
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common finding in CRPS patients  [7, 25] , and our pa-
tients showed high stress symptoms scores and evidence 
of long-lasting chronic neuropathic pain.
 Anandamide found in peripheral blood is synthesized 
by nucleated blood cells  [24] ; the primary stimulus lead-
ing to increased endocannabinoid synthesis in blood cells 
is, however, unknown. The peripheral ECS in humans 
has been shown to be activated by stressful physical exer-
cise  [26] and deactivated by the induction of general an-
esthesia which leads to a pronounced stress reduction 
 [27] . Furthermore, elevated anandamide levels have been 
described in patients with a stress-related disorder, name-
ly fibromyalgia  [28] . Likewise, in animals, massive emo-
tional stress has been identified as a key stimulus regulat-
ing endocannabinoid synthesis  [29] .
 The pathophysiological relevance of the enhanced 
anandamide levels in CRPS patients is still unclear. Using 
various experimental paradigms which involved stress, 
pain and memory  [30–32] , inhibitory endocannabinoid 
activity has been demonstrated in the amygdala, a key 
brain area for the encoding and consolidation of trau-
matic information  [33] . One could therefore speculate 
that the increased activity of the peripheral ECS observed 
in our study is related to continuous stress exposure and 
suggests a possible protective role for the ECS in the mod-
ulation of neuropathic pain and pain memory  [34] . These 
protective effects of endocannabinoids may also include 
stress-induced analgesia, both on a central  [35] and a pe-
ripheral level  [15] . Using murine models, stress induced a 
rapid anandamide release in several central nervous sys-
tem regions resulting in stress-induced analgesia via CB 1 
receptors  [35, 36] . In addition, a very recent study has 
shown that endocannabinoids mediate analgesia via 
stimulation of peripheral CB 1 receptors in mice  [15] .
 A further protective effect of the ECS may result from 
well-known anti-inflammatory effects via CB 2 receptors 
 [37] on a variety of innate and adaptive immune func-
tions  [38] . Animal and in vitro experiments revealed that 
cellular effects of cannabinoids include modulation of 
chemotaxis of macrophage-like cells  [39] , migration of 
natural killer cells  [40] , modification of oxidative burst
of neutrophils  [41] , and attenuation of B and T cell subset 
formations  [42] , thereby contributing to anti-inflam-
matory host defense mechanisms of the organism. In
fact, inflammation control by enhanced anandamide 
 levels has been described for experimentally induced co-
lon inflammation  [43] , cholera toxin-induced diarrhea 
 [44] , and in patients with inflammatory gastrointestinal 
diseases  [45] . In patients with another stress-related dis-
order, namely fibromyalgia, a strong, positive relation-
ship between anandamide levels and the adhesive and 
phagocytic functions of neutrophils was found. More-
over, multiple backward regression analysis revealed 
plasma concentration of anandamide to be the main fac-
tor in determining adhesion and phagocytosis capacity 
of neutrophils  [28] . Thus, the upregulation of peripheral 
anandamide levels seen in our patients might be regarded 
as an endogenous mechanism to protect from pain and 
to limit inflammation.









Trauma before ongoing of CRPS
1 53 20 distal radial fracture
2 49 53 lateral meniscal lesion 
3 36 92 epicondylitis humeroscapularis
4 53 25 cubital tunnel syndrome
5 52 5 rhizarthrosis 
6 50 3 scaphoidal fracture
7 48 8 Weber C fracture
8 44 3 distal radial fracture
9 20 10 contusion of the knee and lower leg





















Healthy volunteers CRPS patients
***
 Fig. 1. Comparison of anandamide plasma levels between CRPS 
patients and age- and sex-matched healthy controls (10 subjects 
each).  * * * p  ! 0.001, Student’s t test. To convert ng/ml to pmol/ml, 
multiply by 2.9. Data are means  8 standard deviation. 
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 Our study has several limitations, however. We stud-
ied only a small number of subjects, and this makes it 
difficult to generalize our findings to other patient groups 
with CRPS. Additionally, interindividual differences pre-
ponderate in such small patient groups. On the other 
hand, the patient and the control groups in our study 
were well matched, and the differences between both 
groups with regard to the hypothesis under study were 
large and statistically significant. A further limitation is 
that we determined only anandamide and did not mea-
sure other important endocannabinoids such as 2-AG. 
The determination of 2-AG carries several methodologi-
cal problems, however, which result from spontaneous 
isomerization to biologically inactive 1-AG  [46, 47] which 
may occur in vivo and in vitro with the consequence of 
imprecise measurements  [48] .
 In conclusion, our study has shown for the first time 
that the peripheral ECS is activated in highly stressed in-
dividuals with CRPS. With respect to the pain-limiting 
and anti-inflammatory actions of the endocannabinoid 
anandamide, it is suggested that the elevated anandamide 
level is probably autoprotective and CRPS patients might 




 1 Birklein F: Complex regional pain syndrome. 
J Neurol 2005; 252: 131–138. 
 2 Harden RN, Bruehl S, Stanton-Hicks M, 
Wilson PR: Proposed new diagnostic criteria 
for complex regional pain syndrome. Pain 
Med 2007; 8: 326–331. 
 3 Jänig W, Baron R: Complex regional pain 
syndrome: mystery explained? Lancet Neu-
rol 2003; 2: 687–697. 
 4 Juottonen K, Gockel M, Silen T, Hurri H, 
Hari R, Forss N: Altered central sensorimo-
tor processing in patients with complex re-
gional pain syndrome. Pain 2002; 98: 315–
323. 
 5 Maihöfner C, Baron R, Decol R, Binder A, 
Birklein F, Deuschl G, Handwerker HO, 
Schattschneider J: The motor system shows 
adaptive changes in complex regional pain 
syndrome. Brain 2007; 130: 2671–2687. 
 6 McMahon SB, Cafferty WBJ, Marchand F: 
Immune and glial cell factors as pain media-
tors and modulators. Exp Neurol 2005; 192: 
 444–462. 
 7 Drummond PD, Finch PM, Skipworth S, 
Blockey P: Pain increases during sympathet-
ic arousal in patients with complex regional 
pain syndrome. Neurology 2001; 57: 1296–
1303. 
 8 Kaufmann I, Eisner C, Richter P, Huge V, 
Beyer A, Chouker A, Schelling G, Thiel M: 
Psychoneuroendocrine stress response may 
impair neutrophil function in complex re-
gional pain syndrome. Clin Immunol 2007; 
 125: 103–111. 
 9 Carrier EJ, Patel S, Hillard CJ: Endocannabi-
noids in neuroimmunology and stress. Curr 
Drug Targets CNS Neurol Disord 2005; 4: 
 657–665. 
 10 Grotenhermen F: Pharmacology of cannabi-
noids. Neuro Endocrinol Lett 2004; 25: 14–
23. 
 11 Matsuda LA, Lolait SJ, Brownstein MJ, 
Young AC, Bonner TI: Structure of a canna-
binoid receptor and functional expression
of the cloned cDNA. Nature 1990; 346: 561–
564. 
 12 Galiegue S, Mary S, Marchand J, Dussossoy 
D, Carriere D, Carayon P, Bouaboula M, 
Shire D, Le Fur G, Casellas P: Expression of 
central and peripheral cannabinoid recep-
tors in human immune tissues and leukocyte 
subpopulations. Eur J Biochem 1995; 232: 
 54–61. 
 13 Schatz AR, Lee M, Condie RB, Pulaski JT, 
Kaminski NE: Cannabinoid receptors CB 1 
and CB 2 : a characterization of expression 
and adenylate cyclase modulation within the 
immune system. Toxicol Appl Pharmacol 
1997; 142: 278–287. 
 14 Van der Stelt M, Trevisani M, Vellani V, De 
Petrocellis L, Moriello AS, Campi C, Mc-
Naughton P, Geppetti P, Di Marzo V: Anan-
damide acts as intracellular messenger am-
plifying Ca 2+ influx via TRPV1 channels. 
EMBO J 2005; 24: 3026–3037. 
 15 Agarwal N, Pacher P, Tegeder I, Amaya F, 
Constantin CE, Brenner GJ, Rubino T, Mi-
chalski CW, Marsicano G, Monory K, Mack-
ie K, Marian C, Batkai S, Parolaro D, Fischer 
MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf 
CJ, Kuner R: Cannabinoids mediate analge-
sia largely via peripheral type 1 cannabinoid 
receptors in nociceptors. Nat Neurosci 2007; 
 10: 870–879. 
 16 Ibrahim MM, Rude ML, Stagg NJ, Mata HP, 
Lai J, Vanderah TW, Porreca F, Buckley NE, 
Makriyannis A, Malan TP: CB 2 cannabinoid 
receptor mediation of antinociception. Pain 
2006; 122: 36–42. 
 17 Batkai S, Osei-Hyiaman D, Pan H, El Assal 
O, Rajesh M, Mukhopadhyay P, Hong F, 
Harvey-White J, Jafri A, Hasko G, Huffman 
JW, Gao B, Kunos G, Pacher P: Cannabinoid-
2 receptor mediates protection against he-
patic ischemia/reperfusion injury. FASEB J 
2007; 21: 1788–1800. 
 18 Maresz K, Pryce G, Ponomarev ED, Marsi-
cano G, Croxford JL, Shriver LP, Ledent C, 
Cheng X, Carrier EJ, Mann MK, Giovannoni 
G, Pertwee RG, Yamamura T, Buckley NE, 
Hillard CJ, Lutz B, Baker D, Dittel BN: Direct 
suppression of CNS autoimmune inflamma-
tion via the cannabinoid receptor CB 1 on 
neurons and CB 2 on autoreactive T cells. Nat 
Med 2007; 13: 492–497. 
 19 Tasker J. Endogenous cannabinoids take the 
edge off neuroendocrine responses to stress. 
Endocrinology 2004; 145: 5429–5430. 
 20 Stanton-Hicks M, Jänig W, Hassenbusch S, 
Haddox JD, Boas R, Wilson P: Reflex sympa-
thetic dystrophy – changing concepts and 
taxonomy. Pain 1995; 63: 127–133. 
 21 Bruehl S, Harden RN, Galer BS, Saltz S, Ber-
tram M, Backonja M, Gayles R, Rudin N, 
Bhugra MK, Stanton-Hicks M: External val-
idation of IASP diagnostic criteria for com-
plex regional pain syndrome and proposed 
research diagnostic criteria. Pain 1999; 81: 
 147–154. 
 22 Gerbershagen U: Organisierte Schmerzbe-
handlung – Eine Standortbestimmung. In-
ternist 1986; 27: 459–469. 
 23 Weisaeth L: Torture of a Norwegian ship’s 
crew. The torture, stress reactions and psy-
chiatric after-effects. Acta Psychiatr Scand 
Suppl 1989; 355: 63–72. 
 24 Vogeser M, Hauer D, Christina AS, Huber E, 
Storr M, Schelling G: Release of anandamide 
from blood cells. Clin Chem Lab Med 2006; 
 44: 488–491. 
 25 Grande LA, Loeser JD, Ozuna J, Ashleigh A, 
Samii A: Complex regional pain syndrome 
as a stress response. Pain 2004; 110: 495–
498. 
 26 Sparling PB, Giuffrida A, Piomelli D, Ross-
kopf L, Dietrich A: Exercise activates the en-
docannabinoid system. Neuroreport 2003; 
 14: 2209–2211. 
 Enhanced Anandamide in CRPS Eur Surg Res 2009;43:325–329 329
 27 Schelling G, Hauer D, Azad SC, Schmoelz M, 
Chouker A, Schmidt M, Hornuss C, Ripp-
berger M, Briegel J, Vogeser M: Effect of gen-
eral anesthesia on anandamide blood levels 
in humans. Anesthesiology 2006; 104: 273–
277. 
 28 Kaufmann I, Schelling G, Eisner C, Richter 
HP, Krauseneck T, Vogeser M, Hauer D, 
Campolongo P, Chouker A, Beyer A, Thiel 
M: Anandamide and neutrophil function in 
patients with fibromyalgia. Psychoneuroen-
docrinology 2008; 33: 676–685. 
 29 Fowler CJ: The cannabinoid system and its 
pharmacological manipulation – a review, 
with emphasis upon the uptake and hydroly-
sis of anandamide. Fundam Clin Pharmacol 
2006; 20: 549–562. 
 30 Azad SC, Monory K, Marsicano G, Cravatt 
BF, Lutz B, Zieglgänsberger W, Rammes G: 
Circuitry for associative plasticity in the 
amygdala involves endocannabinoid signal-
ing. J Neurosci 2004; 24: 9953–9961. 
 31 Connell K, Bolton N, Olsen D, Piomelli D, 
Hohmann AG: Role of the basolateral nucle-
us of the amygdala in endocannabinoid-me-
diated stress-induced analgesia. Neurosci 
Lett 2006; 397: 180–184. 
 32 Marsicano G, Wotjak CT, Azad SC, Bisogno 
T, Rammes G, Cascio MG, Hermann H, 
Tang J, Hofmann C, Zieglgänsberger W, Di 
Marzo V, Lutz B: The endogenous cannabi-
noid system controls extinction of aversive 
memories. Nature 2002; 418: 530–534. 
 33 Roozendaal B, Quirarte GL, McGaugh JL: 
Stress-activated hormonal systems and the 
regulation of memory storage. Ann NY Acad 
Sci 1997; 821: 247–258. 
 34 Pertwee RG: Cannabinoid receptors and 
pain. Prog Neurobiol 2001; 63: 569–611. 
 35 Hohmann AG, Suplita RL, Bolton NM, Neely 
MH, Fegley D, Mangieri R, Krey JF, Walker 
JM, Holmes PV, Crystal JD, Duranti A, Ton-
tini A, Mor M, Tarzia G, Piomelli D: An 
 endocannabinoid mechanism for stress-
 induced analgesia. Nature 2005; 435: 1108–
1112. 
 36 Suplita RL, Farthing JN, Gutierrez T, Hoh-
mann AG: Inhibition of fatty-acid amide 
hydrolase enhances cannabinoid stress-in-
duced analgesia: sites of action in the dorso-
lateral periaqueductal gray and rostral ven-
tromedial medulla. Neuropharmacology 
2005; 49: 1201–1209. 
 37 Ullrich O, Merker K, Timm J, Tauber S: Im-
mune control by endocannabinoids – new 
mechanisms of neuroprotection? J Neuro-
immunol 2007; 184: 127–135. 
 38 Klein TW, Newton C, Larsen K, Lu L, Per-
kins I, Nong L, Friedman H: The cannabi-
noid system and immune modulation. J Leu-
koc Biol 2003; 74: 486–496. 
 39 Cabral GA, Marciano-Cabral F: Cannabi-
noid-mediated exacerbation of brain infec-
tion by opportunistic amebae. J Neuroim-
munol 2004; 147: 127–130. 
 40 Kishimoto S, Muramatsu M, Gokoh M, Oka 
S, Waku K, Sugiura T: Endogenous cannabi-
noid receptor ligand induces the migration 
of human natural killer cells. J Biochem (To-
kyo) 2005; 137: 217–223. 
 41 Kraft B, Kress HG: Indirect CB 2  receptor and 
mediator-dependent stimulation of human 
whole-blood neutrophils by exogenous and 
endogenous cannabinoids. J Pharmacol Exp 
Ther 2005; 315: 641–647. 
 42 Ziring D, Wei B, Velazquez P, Schrage M, 
Buckley NE, Braun J: Formation of B and T 
cell subsets require the cannabinoid receptor 
CB 2 . Immunogenetics 2006; 58: 714–725. 
 43 D’Argenio G, Valenti M, Scaglione G, Cosen-
za V, Sorrentini I, Di Marzo V: Up-regulation 
of anandamide levels as an endogenous 
mechanism and a pharmacological strategy 
to limit colon inflammation. FASEB J 2006; 
 20: 568–570. 
 44 Izzo AA, Capasso F, Costagliola A, Bisogno 
T, Marsicano G, Ligresti A, Matias I, Capasso 
R, Pinto L, Borrelli F, Cecio A, Lutz B, Mas-
colo N, Di Marzo V: An endogenous canna-
binoid tone attenuates cholera toxin-induced 
fluid accumulation in mice. Gastroenterol-
ogy 2003; 125: 765–774. 
 45 Di Marzo V, Izzo AA: Endocannabinoid 
overactivity and intestinal inflammation. 
Gut 2006; 55: 1373–1376. 
 46 Van de Voorde S, Saha B, Mahadevan A, 
Razdan RK, Pertwee RG, Martin BR, Fowler 
CJ: Influence of the degree of unsaturation of 
the acyl side chain upon the interaction of 
analogues of 1-arachidonoylglycerol with 
monoacylglycerol lipase and fatty acid am-
ide hydrolase. Biochem Biophys Res Com-
mun 2005; 337: 104–109. 
 47 van der Stelt SM, van Kuik JA, Bari M, van 
Zadelhoff G, Leeflang BR, Veldink GA, Fi-
nazzi-Agro A, Vliegenthart JF, Maccarrone 
M: Oxygenated metabolites of anandamide 
and 2-arachidonoylglycerol: conformational 
analysis and interaction with cannabinoid 
receptors, membrane transporter, and fatty 
acid amide hydrolase. J Med Chem 2002; 45: 
 3709–3720. 
 48 Vogeser M, Schelling G: Pitfalls in measur-
ing the endocannabinoid 2-arachidonoyl 
glycerol in biological samples. Clin Chem 
Lab Med 2007; 45: 1023–1025. 
 
